Last $290.54 USD
Change Today -0.94 / -0.32%
Volume 1.3M
BIIB On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

biogen idec inc (BIIB) Snapshot

Open
$291.00
Previous Close
$291.48
Day High
$296.00
Day Low
$289.76
52 Week High
03/19/14 - $358.89
52 Week Low
06/21/13 - $194.66
Market Cap
68.7B
Average Volume 10 Days
2.2M
EPS TTM
$7.82
Shares Outstanding
236.4M
EX-Date
--
P/E TM
37.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOGEN IDEC INC (BIIB)

biogen idec inc (BIIB) Details

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin’s lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company’s products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company’s Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company’s Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.

6,850 Employees
Last Reported Date: 02/6/14
Founded in 1985

biogen idec inc (BIIB) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.3M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $635.8K
Executive Vice President of Research & Develo...
Total Annual Compensation: $657.9K
Executive Vice President of Pharmaceutical Op...
Total Annual Compensation: $552.0K
Executive Vice President of Human Resources
Total Annual Compensation: $586.5K
Compensation as of Fiscal Year 2012.

biogen idec inc (BIIB) Key Developments

Biogen Idec Appoints Adam M. Koppel as Senior Vice President and Chief Strategy Officer, Effective from May 15, 2014

Biogen Idec announced the appointment of Adam M. Koppel, M.D., Ph.D., as senior vice president and chief strategy officer, effective May 15, 2014. Dr. Koppel will be responsible for leading corporate strategy and portfolio management, as well as ensuring that disease strategies clearly align with the corporate strategy. He will report to George Scangos, Ph.D., chief executive officer, and will be a member of the Biogen Idec management team.

Biogen Idec and Swedish Orphan Biovitrum AB Announce Positive Top-Line Efficacy and Safety Results from Phase 3 Pediatric Study of Investigational Therapy Eloctate for Hemophilia

Biogen Idec and Swedish Orphan Biovitrum AB announced that it has released positive top-line results of the Kids A-LONG Phase 3 clinical study that evaluated the safety and efficacy of ELOCTATE, an investigational recombinant factor VIII Fc fusion protein product candidate, in children with severe hemophilia A. ELOCTATE was generally well-tolerated and no inhibitors were detected. Efficacy analyses showed twice-weekly prophylactic dosing with ELOCTATE maintained low bleeding rates in children. Kids A-LONG is the first study to evaluate a long-lasting, investigational hemophilia therapy in children under 12 years old. ELOCTATE was developed using a process called Fc fusion and is designed to prolong the circulation of infused clotting factor in the body. The successful completion of this study will support applications for pediatric indications globally and is an important step to obtaining marketing authorization in Europe. The European Medicines Agency requires the inclusion of pediatric study data in a marketing application for a new hemophilia therapy. Kids A-LONG investigated the safety, efficacy and pharmacokinetics of ELOCTATE in previously treated children under 12 years old with severe hemophilia A. The primary endpoint of the study was to evaluate the frequency of inhibitor development and none were detected. Secondary endpoints included the overall and spontaneous annualized bleeding rates, or projected number of yearly bleeding episodes, and the number of infusions used to prevent and treat bleeding episodes. In the study, the relative increase in half-life in children with severe hemophilia A was consistent with the 1.5-fold increase in half-life seen in the A-LONG study of adults and adolescents. Children treated prophylactically with ELOCTATE had an overall median ABR of 2.0 and a median ABR for spontaneous bleeds of 0.0. 46% of participants in the study experienced zero bleeding episodes. Overall, ninety 3% of bleeding episodes were controlled by one to two infusions of ELOCTATE. Additional analyses of the Kids A-LONG study are ongoing, and the companies plan to present detailed results at a future scientific meeting.

Biogen Idec Receives Approval from U.S. Food and Drug Administration for ALPROLIX

Biogen Idec announced that the U.S. Food and Drug Administration approved ALPROLIX(TM) [Coagulation Factor IX (Recombinant), Fc Fusion Protein], the first recombinant, DNA derived hemophilia B therapy with prolonged circulation in the body. ALPROLIX is indicated for the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with hemophilia B. The therapy is shown to reduce bleeding episodes with prophylactic (protective) infusions starting at least a week apart. The approval of ALPROLIX is the first significant advance in hemophilia B treatment in more than 17 years. The therapy is clinically proven to reduce bleeding episodes with a favorable safety and tolerability profile. It is developed using a process called Fc fusion and is the first hemophilia therapy to demonstrate prolonged circulation in the body, which has been shown in adults and adolescents with hemophilia to extend the time between prophylactic infusions. The FDA approval of ALPROLIX is a significant milestone for the hemophilia B community, and represents an important first step in the commitment to transform the care of people with hemophilia.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIIB:US $290.54 USD -0.94

BIIB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $48.55 USD +0.43
Bristol-Myers Squibb Co $49.46 USD +0.35
Celgene Corp $141.51 USD -0.35
CSL Ltd A$67.68 AUD +0.15
Shire PLC 2,925 GBp +25.00
View Industry Companies
 

Industry Analysis

BIIB

Industry Average

Valuation BIIB Industry Range
Price/Earnings 37.2x
Price/Sales 9.9x
Price/Book 8.0x
Price/Cash Flow 31.2x
TEV/Sales 9.6x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGEN IDEC INC, please visit www.biogenidec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.